(2nd article) FDA Safety Alerts for Human Medical Products > Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication - Modified Dosing Recommendations

Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp)

Response Rates | 2010 National Physician Survey Canada

Response Rates	Contact mode
Completion mode	Paper	Email
Paper	17.5%%	2.6%
Online	2.0%	14.8%
Subtotal Survey Respondents	19.5%	17.4%
Did not respond	80.5%	82.6%
Total	100%	100%

abstract- American Journal of Obstetrics and Gynecology : Patients with cervical cancer: why did screening not prevent these cases?

abstract- American Journal of Obstetrics and Gynecology : Factors associated with age of onset and type of menopause in a cohort of UK women